Journal
TRANSLATIONAL AND CLINICAL PHARMACOLOGY
Volume 29, Issue 1, Pages 53-64Publisher
KSCPT
DOI: 10.12793/tcp.2021.29.e5
Keywords
Fixed-dose Combination; Fimasartan; Amlodipine; Hydrochlorothiazide; Pharmacokinetics
Categories
Funding
- Boryung Pharmaceutical Co., Ltd., Seoul, Republic of Korea
Ask authors/readers for more resources
The new FDC of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg demonstrated similar PK profiles to the corresponding loose combination, and both treatments were well tolerated.
For the treatment of hypertension, fixed-dose combinations (FDCs) of antihypertensive drugs can provide complementary benefits from improved compliance and cost-effectiveness compared with loose combinations of corresponding drugs. A new FDC of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg is undergoing clinical development. A randomized, open-label, single-dose, 3-period, 3-sequence, partially replicated crossover phase 1 study was conducted to compare the pharmacokinetics (PKs) between the FDC of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a loose combination of a dual-combination FDC (fimasartan/amlodipine 60/10 mg) and hydrochlorothiazide 25 mg. Sixty healthy subjects were randomized, and 55 subjects completed the study. Serial blood samples were collected, and plasma concentrations of fimasartan, amlodipine and hydrochlorothiazide were measured to analyze PK parameters. The PK profiles of the FDC were similar to those of the loose combinations. The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) of the FDC to loose combinations for the maximum plasma concentration (C-max) and area under the curve until the last measurable time point (AUC(last)) were within the conventional bioequivalent range of 0.80 to 1.25. The GMRs and 90% CIs of fimasartan, amlodipine and hydrochlorothiazide were 1.0163 (0.8681-1.1898), 0.9595 (0.9256-0.9946), and 1.1294 (1.0791-1.1821) for C-max and 1.0167 (0.9347-1.1059), 0.9575 (0.9317-0.9841), and 1.0561 (1.0170-1.0967) for AUC(last), respectively. Both the FDC and loose combinations were well tolerated. In conclusion, the FDC of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg showed similar PK profiles to those of the corresponding loose combination, and both treatments were well tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available